Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809926 · ClinicalTrials.gov registry record · Phase 4
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 451
- Enrollment target
NCT00809926 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 451 participants.
The verdict
NCT00809926, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 451 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension.
Interventions
- DRUG Valsartan
- DRUG Valsartan/aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809926
The ClinicalTrials.gov registry entry for NCT00809926 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 451 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valsartan is the first listed.
NCT00809926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809926 about?
NCT00809926 is a clinical study titled "8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension". To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension.
What is the current status of trial NCT00809926?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 451 participants. The study started on 2009-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00809926?
The interventions under investigation include: Valsartan (DRUG), Valsartan/aliskiren (DRUG).
Who is sponsoring clinical trial NCT00809926?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.